Salvatore Cassese1, Sebastian Kufner2, Erion Xhepa1, Robert A Byrne1, Johanna Kreutzer1, Tareq Ibrahim3, Klaus Tiroch4, Marco Valgimigli5, Ralph Tölg6, Massimiliano Fusaro1, Heribert Schunkert1,7, Karl-Ludwig Laugwitz3,7, Julinda Mehilli8,7, Adnan Kastrati1,7. 1. Deutsches Herzzentrum München, Technische Universität München, Munich, Germany. 2. Deutsches Herzzentrum München, Technische Universität München, Munich, Germany. sebastian.kufner@gmx.de. 3. 1. medizinische Klinik, Klinikum rechts der Isar, Technische Universität München, Lazarettstrasse 36, 80636, Munich, Germany. 4. Department of Cardiology, Helios Klinikum Wuppertal, Universität Witten/Herdecke, Wuppertal, Germany. 5. Department of Cardiology, Bern University Hospital, Bern, Switzerland. 6. Herzzentrum der Segeberger Kliniken Gruppe, Bad Segeberg, Germany. 7. DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany. 8. Department of Cardiology, Ludwig-Maximilians-Universität, Munich, Germany.
Abstract
BACKGROUND: In percutaneous coronary intervention (PCI) patients new-generation drug-eluting stent (DES) has reduced adverse events in comparison to early-generation DES. The aim of the current study was to investigate the long-term clinical efficacy and safety of new-generation DES versus early-generation DES for PCI of unprotected left main coronary artery (uLMCA) disease. METHODS: The patient-level data from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 randomized trials were pooled. The clinical outcomes of PCI patients assigned to new-generation DES (everolimus- or zotarolimus-eluting stent) versus early-generation DES (paclitaxel- or sirolimus-eluting stent) were studied. The primary endpoint was the composite of death, myocardial infarction (MI), target lesion revascularization and stroke (MACCE, major adverse cardiac and cerebrovascular event). RESULTS: In total, 1257 patients were available. At 3 years, the risk of MACCE was comparable between patients assigned to new-generation DES or early-generation DES (28.2 versus 27.5 %, hazard ratio-HR 1.03, 95 % confidence intervals-CI 0.83-1.26; P = 0.86). Definite/probable stent thrombosis was low and comparable between new-generation DES and early-generation DES (0.8 versus 1.6 %, HR 0.52, 95 % CI 0.18-1.57; P = 0.25); in patients treated with new-generation DES no cases occurred beyond 30 days. Diabetes increased the risk of MACCE in patients treated with new-generation DES but not with early-generation DES (P interaction = 0.004). CONCLUSIONS: At 3-year follow-up, a PCI with new-generation DES for uLMCA disease shows comparable efficacy to early-generation DES. Rates of stent thrombosis were low in both groups. Diabetes significantly impacts the risk of MACCE at 3 years in patients treated with new-generation DES for uLMCA disease. ClinicalTrials.gov Identifiers: NCT00133237; NCT00598637.
RCT Entities:
BACKGROUND: In percutaneous coronary intervention (PCI) patients new-generation drug-eluting stent (DES) has reduced adverse events in comparison to early-generation DES. The aim of the current study was to investigate the long-term clinical efficacy and safety of new-generation DES versus early-generation DES for PCI of unprotected left main coronary artery (uLMCA) disease. METHODS: The patient-level data from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 randomized trials were pooled. The clinical outcomes of PCI patients assigned to new-generation DES (everolimus- or zotarolimus-eluting stent) versus early-generation DES (paclitaxel- or sirolimus-eluting stent) were studied. The primary endpoint was the composite of death, myocardial infarction (MI), target lesion revascularization and stroke (MACCE, major adverse cardiac and cerebrovascular event). RESULTS: In total, 1257 patients were available. At 3 years, the risk of MACCE was comparable between patients assigned to new-generation DES or early-generation DES (28.2 versus 27.5 %, hazard ratio-HR 1.03, 95 % confidence intervals-CI 0.83-1.26; P = 0.86). Definite/probable stent thrombosis was low and comparable between new-generation DES and early-generation DES (0.8 versus 1.6 %, HR 0.52, 95 % CI 0.18-1.57; P = 0.25); in patients treated with new-generation DES no cases occurred beyond 30 days. Diabetes increased the risk of MACCE in patients treated with new-generation DES but not with early-generation DES (P interaction = 0.004). CONCLUSIONS: At 3-year follow-up, a PCI with new-generation DES for uLMCA disease shows comparable efficacy to early-generation DES. Rates of stent thrombosis were low in both groups. Diabetes significantly impacts the risk of MACCE at 3 years in patients treated with new-generation DES for uLMCA disease. ClinicalTrials.gov Identifiers: NCT00133237; NCT00598637.
Entities:
Keywords:
Drug-eluting stent; Everolimus; Left main coronary artery; Paclitaxel; Percutaneous coronary intervention; Sirolimus; Zotarolimus
Authors: Enno Boudriot; Holger Thiele; Thomas Walther; Christoph Liebetrau; Peter Boeckstegers; Tilmann Pohl; Bruno Reichart; Harald Mudra; Florian Beier; Brigitte Gansera; Franz-Josef Neumann; Michael Gick; Thomas Zietak; Steffen Desch; Gerhard Schuler; Friedrich-Wilhelm Mohr Journal: J Am Coll Cardiol Date: 2011-02-01 Impact factor: 24.094
Authors: I Akin; C Naber; G Sabin; M Hochadel; J Senges; K H Kuck; C Nienaber; G Richardt; Ralph Tölg Journal: Clin Res Cardiol Date: 2013-05-17 Impact factor: 5.460
Authors: Tullio Palmerini; Giuseppe Biondi-Zoccai; Diego Della Riva; Andrea Mariani; Manel Sabaté; Pieter C Smits; Christoph Kaiser; Fabrizio D'Ascenzo; Giacomo Frati; Massimo Mancone; Philippe Genereux; Gregg W Stone Journal: J Am Coll Cardiol Date: 2013-11-06 Impact factor: 24.094
Authors: Aloke V Finn; Gaku Nakazawa; Michael Joner; Frank D Kolodgie; Erik K Mont; Herman K Gold; Renu Virmani Journal: Arterioscler Thromb Vasc Biol Date: 2007-05-17 Impact factor: 8.311
Authors: Sripal Bangalore; Sunil Kumar; Mario Fusaro; Nicholas Amoroso; Michael J Attubato; Frederick Feit; Deepak L Bhatt; James Slater Journal: Circulation Date: 2012-05-14 Impact factor: 29.690
Authors: Marie-Claude Morice; Patrick W Serruys; A Pieter Kappetein; Ted E Feldman; Elisabeth Ståhle; Antonio Colombo; Michael J Mack; David R Holmes; James W Choi; Witold Ruzyllo; Grzegorz Religa; Jian Huang; Kristine Roy; Keith D Dawkins; Friedrich Mohr Journal: Circulation Date: 2014-04-03 Impact factor: 29.690
Authors: Aurel Toma; Barbara E Stähli; Michael Gick; Cathérine Gebhard; Thomas Nührenberg; Kambis Mashayekhi; Miroslaw Ferenc; Franz-Josef Neumann; Heinz Joachim Buettner Journal: Clin Res Cardiol Date: 2017-02-24 Impact factor: 5.460
Authors: Christoph Varenhorst; Martin Lindholm; Giovanna Sarno; Göran Olivecrona; Ulf Jensen; Johan Nilsson; Jörg Carlsson; Stefan James; Bo Lagerqvist Journal: Clin Res Cardiol Date: 2018-04-17 Impact factor: 5.460